Specialised Therapeutics' Breakthrough Brain Tumour Visualisation Drug GLIOLAN(R) Approved for Use in New Zealand

- Medsafe has approved GLIOLAN® for marketing and distribution in New Zealand

- GLIOLAN is under consideration for reimbursement as a "high priority" for use in all New Zealand public hospitals

- Phase III study shows complete resection rates and 6-month progression-free survival is doubled in patients receiving GLIOLAN[1]

Sep 18, 2015, 06:00 ET from Specialised Therapeutics Australia

$countyNameToPathMap.put("sp